The CANTOS Trial: One Important Step for Clinical Cardiology but a Giant Leap for Vascular Biology.
Accepted version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Baylis, Richard A
Gomez, Delphine
Mallat, Ziad https://orcid.org/0000-0003-0443-7878
Pasterkamp, Gerard
Owens, Gary K
Abstract
The results of the CANTOS trial provide exciting evidence in support of the inflammatory hypothesis of atherosclerosis in humans, and is the first phase III clinical trial to show clinical benefit of a targeted anti-inflammatory therapy. However, the modest overall clinical benefit and safety concerns with increased susceptibility to fatal infections indicate that we need much more work in this critical area.
Description
Keywords
atherosclerosis, coronary artery disease, inflammation, interleukins, translational medical research, Anti-Inflammatory Agents, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Atherosclerosis, Cardiology, Clinical Trials, Phase III as Topic, Coronary Artery Disease, Humans, Randomized Controlled Trials as Topic, Treatment Outcome
Journal Title
Arterioscler Thromb Vasc Biol
Conference Name
Journal ISSN
1079-5642
1524-4636
1524-4636
Volume Title
37
Publisher
Ovid Technologies (Wolters Kluwer Health)
Publisher DOI
Sponsorship
British Heart Foundation (RG/15/11/31593)